NEW YORK (GenomeWeb News) – In a genomics market where new approaches are supposed to bury older ones, fluorescence in situ hybridization is proving to be an exception.
Connective Tissue Gene Tests (CTGT) has added 21 new assays to its menu of molecular diagnostics for inherited disorders affecting connective tissues.
SciGene recently introduced its CytoBrite Slide Incubation System for performing fluorescence in situ hybridization and in situ hybridization protocols on between one and 12 slides using Peltier technology for rapid heating and cooling.
SciGene this week launched CytoZyme Stabilized Pepsin, an advanced liquid formulation of pepsin for pre-treating tissue samples in nucleic acid probe-based cytogenetic assays.
Bioline, a subsidiary of Meridian Bioscience, this week launched its Isolate II range of nucleic acid purification kits.
SciGene this week launched its Hyb-Ice Thermal Profiling System, which it is claims is a "affordable and flexible alternative" to standard thermal cyclers on the market for temperature profiling.
By Justin Petrone
Microarray tool vendor SciGene has developed a new microsample incubation system that it will ship to early adopters this quarter ahead of a full launch later this year.
The manufacturing and supply deal marks BlueGnome's entry into the microarray hardware market.
BlueGnome's increased sales to customers in different geographies prompted a decision to directly offer all laboratory equipment associated with microarray processing.
Affymetrix's GeneChip Rice 44K SNP Genotyping Array, QuantiScientifics' A2 DxA MicroArray System, SciGene's Hybex Incubator Insert
Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.
US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.
A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.
In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.